Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Treace Medical Concepts (TMCI) Shares Outstanding (2020 - 2025)

Treace Medical Concepts' Shares Outstanding history spans 6 years, with the latest figure at $63.9 million for Q4 2025.

  • For Q4 2025, Shares Outstanding rose 2.41% year-over-year to $63.9 million; the TTM value through Dec 2025 reached $63.9 million, up 2.41%, while the annual FY2025 figure was $63.9 million, 2.41% up from the prior year.
  • Shares Outstanding reached $63.9 million in Q4 2025 per TMCI's latest filing, roughly flat from $63.7 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $63.9 million in Q4 2025 to a low of $38.1 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $58.4 million, with a median of $61.6 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding: tumbled 81.96% in 2021, then skyrocketed 726.6% in 2022.
  • A 5-year view of Shares Outstanding shows it stood at $54.2 million in 2021, then rose by 2.67% to $55.6 million in 2022, then rose by 11.0% to $61.7 million in 2023, then rose by 0.99% to $62.4 million in 2024, then increased by 2.41% to $63.9 million in 2025.
  • Per Business Quant, the three most recent readings for TMCI's Shares Outstanding are $63.9 million (Q4 2025), $63.8 million (Q3 2025), and $63.0 million (Q2 2025).